ClinConnect ClinConnect Logo
Search / Trial NCT02539745

Associations of Vitamin D Deficiency and Vitamin D Receptor Polymorphisms With the Risk of Primary Open-angle Glaucoma

Launched by LV YINGJUAN · Aug 31, 2015

Trial Information

Current as of June 23, 2025

Completed

Keywords

Vitamin D Primary Open Angle Glaucoma

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • intraocular pressure greater than 22 mmHg with two or more medications
  • wide anterior chamber angle
  • glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect)
  • visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry
  • Exclusion Criteria:
  • the presence of any secondary glaucoma including exfoliation syndrome or a history of ocular trauma
  • high myopia
  • macular degeneration
  • other ocular diseases
  • a known history of systemic diseases and administration of vitamin D3 or other analog

About Lv Yingjuan

Lv Yingjuan is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a strong commitment to ethical practices and regulatory compliance, the organization specializes in designing and conducting clinical trials across various therapeutic areas. Leveraging a robust network of experienced professionals and cutting-edge technology, Lv Yingjuan aims to facilitate the efficient development of new treatments while ensuring the highest standards of safety and efficacy. Their collaborative approach fosters partnerships with healthcare institutions and research organizations, driving forward the mission of enhancing global health through scientific discovery.

Locations

Tianjin, Tianjin, China

Patients applied

0 patients applied

Trial Officials

xiaorong li

Study Director

Tianjin Medical University Eye Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials